A new white paper, provided by Dr. Nina Lathia, details the critical elements of an effective pharmacoeconomics (PE) analysis. Dr. Lathia draws on her background as a health economist and pharmacist to offer insight into PE analyses. In addition to clear decision-making processes when comparing drugs for disparate disease states, the white paper also discusses the importance of selecting the right comparator drug.
Dr Lathia remarks, “I work one-on-one with drug formulary managers, clinical pharmacy managers, clinical pharmacists, and other decision-makers at PBM organizations. I’d like to take what I’ve learned and taught to walk you through 10 critical questions that will help you better evaluate new drugs. This will help your achieve the best possible health outcomes for your plan members and support drug plan sustainability at your organization.” Read the white paper here.
(Source: Nina Lathia, Healthcare Decision Making, 2020)